Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at $3.36 on Friday. Achillion Pharmaceuticals, Inc. has a fifty-two week low of $2.95 and a fifty-two week high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. During the same period in the previous year, the firm posted ($0.15) earnings per share. analysts expect that Achillion Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/johnson-johnson-sells-18367346-shares-of-achillion-pharmaceuticals-inc-achn-stock/1722956.html.

ACHN has been the subject of a number of recent research reports. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 14th. Ladenburg Thalmann Financial Services dropped their price objective on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a research report on Tuesday, September 12th. Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub cut Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $5.29.

A number of institutional investors and hedge funds have recently bought and sold shares of ACHN. UBS Asset Management Americas Inc. grew its holdings in Achillion Pharmaceuticals by 83.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 24,471 shares during the period. Parametric Portfolio Associates LLC grew its holdings in Achillion Pharmaceuticals by 304.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 103,263 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 77,748 shares during the period. Teachers Advisors LLC grew its holdings in Achillion Pharmaceuticals by 42.9% in the 1st quarter. Teachers Advisors LLC now owns 1,347,858 shares of the biopharmaceutical company’s stock valued at $5,674,000 after buying an additional 404,317 shares during the period. TIAA CREF Investment Management LLC grew its holdings in Achillion Pharmaceuticals by 2.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 407,750 shares of the biopharmaceutical company’s stock valued at $1,717,000 after buying an additional 10,558 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Achillion Pharmaceuticals by 7.2% in the 1st quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock valued at $40,357,000 after buying an additional 646,415 shares during the period. Institutional investors own 75.70% of the company’s stock.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.